References
1. Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic fibrosis. Prz Gastroenterol 2014;9(3):136–141.
2. Betapudi B, Aleem A, Kothadia JP. Cystic Fibrosis And Liver Disease. StatPearls Publishing; 2020.
3. Paranjape SM, Mogayzel PJ. Cystic fibrosis in the era of precision medicine. Paediatr Respir Rev 2018;25:64–72.
4. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatch T, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38(1):59–69.
5. Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23(2):263–277.
6. Minagawa N, Nagata J, Shibao K, Masyuk AI, Gomes DA, Rodrigues MA, Lesage G, Akiba Y, Kaunitz JD, Ehrlich BE, et al. Cyclic AMP Regulates Bicarbonate Secretion in Cholangiocytes Through Release of ATP Into Bile. Gastroenterology 2007;133(5):1592–1602.
7. Siano M, De Gregorio F, Boggia B, Sepe A, Ferri P, Buonpensiero P, Di Pasqua A, Raia V. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig Liver Dis 2010;42(6):428–431.
8. Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease-another black box in hepatology. Int J Mol Sci 2014;15(8):13529–13549.
9. Stollar F, Adde FV, Cunha MT, Leone C, Rodrigues JC. Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. Clinics 2011;66(6):979–983.
10. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. J Cyst Fibros 2018;17(2):218–227.
11. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A. Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology 2002;36(6):1374–1382.
12. Al-Mahroos F. Cystic fibrosis in Bahrain incidence, phenotype, and outcome. J Trop Pediatr 1998;44(1):35–39.
13. Rawashdeh M, Manal H. Cystic fibrosis in Arabs: A prototype from Jordan. Ann Trop Paediatr 2000;20(4):283–285.
14. Naguib ML, Schrijver I, Gardner P, Pique LM, Doss SS, Abu Zekry MA, Aziz M, Nasr SZ. Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis. J Cyst Fibros 2007;6(2):111–116.
15. Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, Ling SC. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol 2016;14(8):1207-1215.e3.
16. Sharma DG. Cystic Fibrosis Treatment & Management: Approach Considerations, Diet and Exercise, Surgical Management of Complications. Medscape Med News 2022.
17. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology 2019;69(4):1648–1656.
18. Fagundes EDT, Roquete ML V., Penna FJ, Reis FJC, Goulart EMA, Duque CG. Fatores de risco da hepatopatia da fibrose cística. J Pediatr (Rio J) 2005;81(6):478–484.
19. Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson D, Szeinberg A, Yahav J, Bujanover Y. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003;15(10).
20. Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021;13(11):1727–1742.
21. Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cmgh 2019;8(2):197–207.
22. Diwakar V, Pearson L, Beath S. Liver disease in children with cystic fibrosis. Paediatr Respir Rev 2001;2(4):340–349.
23. Williams SM, Goodman R, Thomson A, Mchugh K, Lindsell DRM. Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: A 9-year review. Clin Radiol 2002;57(5):365–370.
24. Bock JM, Schien M, Fischer C, Naehrlich L, Kaeding M, Guntinas-Lichius O, Gerber A, Arnold C, Mainz JG. Importance to question sinonasal symptoms and to perform rhinoscopy and rhinomanometry in cystic fibrosis patients. Pediatr Pulmonol 2017;52(2):167–174.
25. Nährlich L, Burkhart M, Wiese Helfen Forschen Heilen B. Deutsches Mukoviszidose. 2015.
26. Minicucci L, Lorini R, Giannattasio A, Colombo C, Iapichino L, Reali MF, Padoan R, Calevo MG, Casciaro R, De Alessandri A, et al. Liver disease as risk factor for cystic fibrosis-related diabetes development. Acta Paediatr Int J Paediatr 2007;96(5):736–739.
27. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, LeGrys VA, Massie J, Parad RB, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008;153(2):S4–S14.
28. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, et al. Genetic modifiers of liver disease in cystic fibrosis. Jama 2009;302(10):1076–1083.
29. Slieker MG, Deckers-Kocken JM, Uiterwaal CSPM, Van Der Ent CK, Houwen RHJ, Colombo C, Battezzati PM, Crosignani A. Risk factors for the development of cystic fibrosis related liver disease [2] (multiple letters). Hepatology 2003;38(3):775–776.
30. Rowland M, Bourke B. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2011;17(6):461–466.
31. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017;2017(9).
32. Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, Ling SC, Narkewicz MR, Leung DH. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis–Associated Liver Disease. Liver Transplant 2019;25(4):640–657.